Summary Severe methotrexate (MTX) toxicity is a proven complication of associations of MTX and non-steroidal anti-inflammatory drugs (NSAIDs). This study investigated the interaction between MTX (50 or 100 mg kg-') and ketoprofen (KP) (3 mg kg-' day-', pretreatment for 8 days) in the rabbit. The drug association induced a reversible increase in blood urea and creatinine. The severity degree of 7-OH-MTX was prepared in our laboratory according to a method previously published (Jacobs et al., 1976) . Briefly, MTX was incubated on rabbit liver homogenate purified in aldehyde oxidase activity. Total recovery was 15% (10 mg of 7-OH-MTX recovered for 75 mg of MTX incubated). The purity of the 7-OH-MTX (96%) was checked by HPLC and by UV and IR spectral analysis (Jacobs et al., 1976) (valency vibration of the -OH radical absorbing at 3,460 cm-').
An unexpected, life-threatening toxicity was recently observed in our institution when high dose methotrexate (MTX) was given concurrently with the non-steroidal antiinflammatory drug (NSAID) ketoprofen (KP) (Thyss et al., 1986) . Simultaneous administration of the two drugs resulted in prolonged and marked enhancement of MTX serum levels. Since then, additional evidence of severe MTX toxicity has been reported when other NSAIDs are given with high dose MTX (Maiche, 1986) and even with low dose MTX (Singh et al., 1986; Daly et al., 1986) . The fact that indomethacin (Maiche, 1986) , naproxen (Singh et al., 1986) and azapropazone (Daly et al., 1986) have also been implicated supports our initial conclusions that the high risk of an association between MTX and KP should be extended to include other NSAIDs. A more recent study (Ahern et al., 1988) analysed the blood kinetics of low dose oral MTX in rheumatoid arthritis when NSAIDs were given conjointly. The authors concluded that despite apparent interaction in individual patients, mean kinetic variables did not differ significantly with and without NSAIDs therapy. This clearly raises the question of the importance of the MTX dose in the intensity of the drug interaction. Another major question is the origin of the interaction. Post-treatment serum creatinine levels were raised in 75% of our cases (Thyss et al., 1986) , but it was hard to determine whether KP itself or overexposure to MTX was responsible for the renal dysfunction. As MTX (Shen & Azarnoff, 1978) and KP (Verbeek et al., 1983) are bound to plasma proteins, possible displacement of MTX from its binding site by KP is another hypothesis. These various observations motivated the present investigation of the interaction between MTX and KP in a laboratory animal to identify its major determinants. The rabbit was selected (Sasaki et al., 1983) because it reproduces the extensive metabolism of MTX into 7-OH-MTX described in patients (Breithaupt & Kuenzlen, 1982; Milano et al., 1983) .
The effects of the MTX dose and duration of KP exposure were analysed. MTX and 7-OH-MTX pharmacokinetics were evaluated and the biological parameters linked to hematopoietic, hepatic and renal functions were monitored. Renal excretion of a representative prostaglandin was also measured in the different experimental situations.
Material and methods Chemicals and equipment MTX chemical purity was 96.1% (Batch 37 859 -Lederle) by HPLC analysis. MTX powder for injection 500 mg (R BelIon) in vials containing MTX sodium equivalent to MTX 500 mg, given at 50 and 100 mg kg-'.
7-OH-MTX was prepared in our laboratory according to a method previously published (Jacobs et al., 1976) . Briefly, MTX was incubated on rabbit liver homogenate purified in aldehyde oxidase activity. Total recovery was 15% (10 mg of 7-OH-MTX recovered for 75 mg of MTX incubated). The purity of the 7-OH-MTX (96%) was checked by HPLC and by UV and IR spectral analysis (Jacobs et al., 1976) 100 mg kg-' (15 animals per dose). Six controls received KP alone and/or saline. The animals were treated i.m. with KP 3 mg kg-' day-' (or, for controls, saline) for 8 days (sequence A) or for 11 days (sequence B, KP being prolonged 3 days after MTX); they received MTX (50 or 100 mg kg-') on day 8 and calcium folinate 0.5 mg kg-' day-' for 3 days after MTX.
Biological samples Blood was taken from the marginal vein of the ear (5 animals per experimental condition). For plasma analysis of biochemical parameters, 2 ml of blood was obtained at the following times: the day before the beginning of pre-treatment (day -8, where day 0 is the day of MTX administration); just before MTX administration, at day 0; after the administration of MTX, and during 2 weeks on days 1, 2, 3, 6, 9 and 14. For the analysis of plasma MTX and 7-OH-MTX, 2ml of blood was obtained at the following times after the MTX i.v. bolus injection: 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 h. Complete blood counts were performed on blood samples collected on EDTA at the same times as indicated for the biological parameters.
Urine was collected for three different animals per experimental condition. Animals were kept in metabolic cages allowing separation of faeces and urine. Urines were cooled to 0-4°C just after mictation, and were collected by 24 h fractions in a temperature-controlled flask containing 1 ml of thimerosal (0.5% in H20), an antiseptic, and niflumic acid 0.5% to inhibit prostaglandin synthetase. Before each new urine collection, the cage was rinsed with H20 (50-75 ml); this aqueous fraction was added to the fraction collected previously. Before deep freezing at -20°C, the total volume was measured, and 20 ml aliquots for 6-keto-PGFI, analysis were stored in conical polypropylene tubes with screw tops; the remaining urines was used for quantitation of MTX and 7-OH-MTX.
Pharmacological and biological parameters MTX and 7-OH-MTX were measured simultaneously by HPLC with UV detection (303 nm) after a solid phase preanalytical extraction (Collier et al., 1982) . The HPLC separation was done in a column Lichrospher 100 RP-18, 250 x 4mm, 5 jAm (Merck) with an isocratic elution (1.3 ml min-) by tetrabutyl ammonium sulphate (Pic A Low UV, Waters Millipore) adjusted to pH 7.5 by H3PO4 and with 36% methanol. The detection was done by spectrophotometry (A= 303 nm, Kratos M 783) . Distribution of the different points between 5.5 x 10-8 M and 5.5 x 10-4 M gave a mean recovery of 97 ± 1% for MTX and 77.5 ± 9% for 7-OH-MTX. Standard curves were plotted between 20 nM and 2 JAM for MTX and between 50 nM and 2 JAM for 7-OH-MTX. The external standard method was used. Responses (peak heights) were linearly related to the respective concentrations of MTX and its metabolite, with r = 0.99 for both compounds.
After thawing, the urine samples were alkalinised with a small volume of 20 N NaOH to ensure the total redissolution of any MTX and 7-OH-MTX that might precipitate during freezing. After centrifugation of a 1 ml aliquot, 30-100 p1 of the supernatant were directly injected into the HPLC system. Calibration curves were obtained from blank urine spiked with known amounts of MTX and 7-OH-MTX (5.5 x 10-7 M to 5.5 x 10-4 M). Due to the presence of interfering endogenous peaks in rabbit urines, a modified HPLC method was used. Briefly, IL Bondapak phenyl columns, 10 tiM (3.9 x 300 mm, Millipore Waters) were equipped with a CN guard column (Millipore Waters (Evans et al., 1986) . A complementary study of plasma binding has been performed in vitro with plasma obtained from rabbits. There were three different experimental conditions: MTX or 7-OH-MTX incubated without KP (control); MTX or 7-OH-MTX plus KP without pre-incubation of plasma with KP; and MTX or 7-OH-MTX plus KP with a pre-incubation of plasma with KP (2 h at 37°C, for simulation of the in vivo conditions). The experimental conditions were as follows: 950 jlA of plasma for rabbit; 25 p1l of stock solution of MTX (or 7-OH-MTX) giving a final concentration of 2 x 10-4 M (this concentration compares well with the mean blood concentrations measured in rabbits 1 and 2 h after the administration of MTX (100 mg kg-'); 25 p1 of a solution of KP giving the respective final concentrations of 2 x 10-4 M, 2 x 10-M and 2 x 10-6 M (for rabbits treated by 3 mg kg-' a mean blood concentration of 4 x 10-M has been described (Populaire et al., 1973) ). The plasma spiked with drugs was incubated for 30 min at 37°C under agitation. It had been previously checked that the steady state of MTX or 7-OH-MTX (2 x 10-4 M) binding in plasma was reached after 30 min of incubation. At the end of the incubation the tubes were immediately refrigerated at 4°C and treated by ultrafiltration as described above. MTX and 7-OH-MTX were analysed by HPLC as described above.
Haematopoietic function was assessed by the circulating erythrocyte, white blood cell and platelet counts. Renal function was evaluated by the plasma levels of Na, K, Cl, urea, creatinine. Hepatic function was checked by measurement of plasma bilirubin, aspartate, and alanine transaminases.
Urinary prostaglandin 6-keto-PGFI,, was measured using the appropriate RIA kit. Urines were extracted before analysis. The extraction step (Powell, 1982) was as follows: after activation of the extraction cartridge by successive passages of 5 ml methanol and 5 ml H20, 20 ml of acidified urines (pH 3-4 with 8 M citric acid) were injected. This was followed by the passage of 10 ml H20; the initial and aqueous eluate were then discarded. Then, 10 ml ethanol 10% in H20 and 10 ml of n-hexan were injected, and the resulting eluates were discarded. Finally, elution by 10 ml of methyl formiate allowed recovery of the prostanoid-containing fraction. This solution was dried in a silicone-coated tube under a stream of nitrogen at exactly 30°C. The dried residue was redisolved in 200 lil ethanol, followed by two times 0.9 ml phosphate buffer, 0.05 M with 0.05% bovine serum albumin, pH 7.4. This optimised process allowed recovery of 93.9% (± 9.2%, n = 37) from a pure labelled standard of 6-keto-PGFI, (Sigma) . A radioactive tracer was added to the initial urines to make sure the prostaglandin was not denatured during the entire extraction process. This last step was done by HPLC as follows (Peters et al., 1983) Figure 2 shows the reversibility of the phenomenon and the normalisation of these biological markers between days 6 and 9 after MTX administration. Blood levels of Na, K, Cl were identical in all experimental conditions.
Analysis of the biological markers of haematopoietic and hepatic functions revealed no evidence of modification of any of them during any of the study conditions. Figure 3a reveals that pretreatment by KP induced a significant (approx. 70%) reduction in urinary excretion of 6-keto-PGFI,. This reduction was not enhanced by prolonging treatment by KP. MTX alone did not affect the urinary levels of 6-keto-PGFI,. Here again, urinary levels of 6-ketoPGFIr. returned to the normal control range 4-11 days after the end of KP treatment (Figure 3b ). 
Discussion
This study was designed to elucidate the origin of the drug interaction between MTX and KP that can have fatal consequences for patients (Thyss et al., 1986) . Our initial observation suggested that renal toxicity was one of the major causes of subsequent overexposure to MTX and ensuing toxicity. However, it was not clear in these cases whether MTX itself (Condit et al., 1969) or KP (Sennesael et al., 1986; Adams et al., 1986) MTX was given at the dose of 100 mg kg-'. KP was given at the dose of 3 mg kg-' day-', during 8 days and stopped the day of MTX injection.
creatinine. Although several pharmacokinetic abnormalities were recently encountered when low dose MTX and NSAIDs were associated for treatment of rheumatoid arthritis, there was no evidence of MTX-related toxicity (Ahern et al., 1988) . This contrasted with earlier reports of fatal consequences after an association of low dose MTX plus NSAIDs (Singh et al., 1986; Daly et al., 1986) . The present study clearly reveals the role of the MTX dose in the intensity of renal toxicity when combined with KP, with the lowest dose (50mgkg-') causing a lesser elevation in blood urea and creatinine.
These results also highlight the pharmacokinetic abnormalities induced by this drug association. The MTX dose had an influence on pharmacokinetic alterations: at 50mgkg-1, only the elimination half-life was significantly prolonged by pretreatment with KP; at 100 mg kg-' more convincing modifications were seen; both total body clearance and renal clearance of MTX were significantly reduced. Interestingly, the fraction of the MTX dose excreted as unchanged drug in urines was reduced, indicating that KP pretreatment affected the absolute recovery of MTX from urine. It is noteworthy that neither renal nor pharmacokinetic abnormalities were influenced by prolonging KP treatment after MTX administration. This indicates that the major cause of interaction is the pretreatment phase by KP. This could have important clinical implications: just stopping KP (or other NSAIDs) the day of the anti-metabolite administration might not be enough to avoid severe toxicity. Analysis of renal excretion of 6-keto-PGFI, illustrates this situation. This prostaglandin was selected because it is the stable metabolite of PGI2 (Schlondorff & Ardaillou, 1986) , mainly synthesised by the kidney (Patrono et al., 1982) , and because prostacyclins play a determinant role in renal blood flow regulation (Dunn, 1987) . Predictably (Carmichael & Shankel, 1985) , pretreatment by KP significantly reduced renal excretion of 6-keto-PGF,C. As MTX is mainly cleared by glomerular filtration (Huang et al., 1979) , pretreatment by KP quite logically impairs renal elimination of the anti-metabolite. The origin of the associated renal toxicity, reflected by the elevation of blood urea and creatinine, is less clear. Prostaglandins affect water metabolism in the kidney (Henrich, 1984) ; effects include antagonism of hydrosmotic activity, inhibition of active chloride transport by the medullary thick ascending limb, and regulation of medullary blood flow. As these three sites are critical for renal production of a dilute urine, intratubular precipitation of MTX or 7-OH-MTX might induce toxic shock in the kidney, further impairing MTX elimination because of reduced glomerular filtration. KP is mainly eliminated in urine as a glucoronide metabolite (Populaire et al., 1973) . Thus, direct competition between KP and MTX at the level of weak acid tubular secretion is another possibility because such competition has been shown between MTX and 8 NSAIDs in rabbit kidney slices, although not with KP (Nierenberg, 1983) . Owing to the moderate MTX binding (Paxton, 1981) and extensive KP binding (Kantor, 1986) to plasma proteins, MTX binding was analysed in the presence of KP. A significant reduction in bound MTX was observed in samples taken 6 h after MTX administration in KP-pretreated animals compared to controls. This could be explained by at least two factors: first, by direct competition between MTX and KP as indicated by the present in vitro data and next, by the displacement of MTX induced by the elevated blood levels of 7-OH-MTX as it has been shown that 7-OH-MTX is a potent competitor for MTX protein binding (Lopez et al., 1986) . As a consequence of this higher MTX-free fraction, a significant increase in the MTX volume of distribution was noted in the presence of KP thus leading to tissue MTX overexposure which increases the potential risk of MTX toxicity.
Surprisingly, although the drug interaction was associated with a significant drug overexposure in this study, there was no haematological toxicity as observed clinically (Thyss et al., 1986) . This may be due to the extensive biotransformation of MTX into 7-OH-MTX in the rabbit (Sasaki et al., 1983) , as confirmed in the present study. Although 7-OH-MTX is an active metabolite (Fabre et al., 1986) , a more recent study concluded that cell growth is only weakly inhibited in the presence of 7-OH-MTX as compared to MTX (Seither et al., 1989) . The preponderance of biotransformation into 7-OH-MTX could have resulted in an overall reduction in drug activity in our study.
In conclusion, the present study reveals the existence of an interaction between MTX and KP and demonstrates its renal origin. Because inhibition of renal prostaglandin synthesis appears to be a key factor, combination of MTX with all types of NSAIDs should be considered with caution. Mere stopping of NSAIDs the day before administration of MTX may be insufficient to eliminate the high risk of drug interaction.
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